Skip to main content

Menu

British National Formulary April 2025 Update

This update contains 11 significant changes, 2 dose changes, 3 new monographs, and 8 new preparations.

Significant Changes:

  • Apixaban: update to structure of dosing for prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and at least one risk factor.
  • Bempedoic acid: new indication and dose for established or at high-risk of atherosclerotic cardiovascular disease.
  • Cardiovascular disease risk assessment and prevention: updated guidance.
  • Dupilumab: new indication and dose for chronic obstructive pulmonary disease.
  • Emtricitabine with tenofovir alafenamide: new indication and dose for pre-exposure prophylaxis of HIV-1.
  • Fezolinetant: risk of drug-induced liver injury and new recommendations on monitoring of liver function before and during treatment [MHRA/CHM advice].
  • GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation [MHRA/CHM advice] (advice in dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, tirzepatide; see example in liraglutide).
  • Immunisation schedule: updated guidance for immunisation against diphtheria, tetanus, pertussis and poliomyelitis in children aged 3 years and 4 months.
  • Naltrexone hydrochloride: new indication and dose for gambling-related harm.
  • Sodium valproate: new advice for male patients already taking sodium valproate [MHRA/CHM advice].
  • Valproic acid: new advice for male patients already taking valproic acid [MHRA/CHM advice].

 

Dose Changes:

  • Ferrous fumarate [update to dosing for iron-deficiency anaemia using oral solution].
  • Sodium feredetate [update to dosing for iron-deficiency anaemia using oral solution].

 

New Monographs:

  • Agamree® [vamorolone].
  • Joenja® [leniolisib].
  • Lunivia® [eszopiclone].

 

New Preparations: Abilify Maintena® 720 mg or 960 mg prolonged-release suspension for injection [aripiprazole]; Bibecfo® 100/6 [beclometasone with formoterol]; Bibecfo® 200/6 [beclometasone with formoterol]; Luforbec® 200/6 [beclometasone with formoterol]; Proxor® 100/6 [beclometasone with formoterol]; Proxor® 200/6 [beclometasone with formoterol]; Vivaire® 100/6 [beclometasone with formoterol]; Vivaire® 200/6 [beclometasone with formoterol].